NewAmsterdam Pharma (NAMS) Interest & Investment Income (2023 - 2026)

NewAmsterdam Pharma has reported Interest & Investment Income for 4 years, with the latest figure at $5.6 million in Q1 2026.

• Quarterly Interest & Investment Income fell 23.14% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.9 million (up 22.42% YoY) and the FY2025 annual result came in at $27.6 million, up 63.45% from the prior year.
• Interest & Investment Income slipped to $5.6 million in Q1 2026 per NAMS's latest filing, from $6.5 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $7.4 million in Q1 2025 and troughed at $943000.0 in Q1 2023.
• A 4-year average of $4.7 million and a median of $4.6 million in 2023 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2024 and 2026: Interest & Investment Income jumped 226.94% in 2024, then retreated 23.14% in 2026.
• Over 4 years, Interest & Investment Income stood at $2.7 million in 2023, then soared by 68.1% to $4.5 million in 2024, then surged by 44.33% to $6.5 million in 2025, then retreated by 12.71% to $5.6 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $5.6 million, $6.5 million, and $6.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.